This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
by Zacks Equity Research
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Humana (HUM) Ups '23 Medicare Advantage Membership Growth View
by Zacks Equity Research
Humana (HUM) expects 2023 net membership gains to be a minimum of 10.9% from the 2022 projection.
Why You Should Retain Centene (CNC) in Your Portfolio Now
by Zacks Equity Research
Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.
What You Need to Know From UnitedHealth's (UNH) Latest Outlook
by Zacks Equity Research
UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.
Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?
by Zacks Equity Research
Cigna (CI) expects its long-term adjusted earnings per share to witness 10-13% average annual growth.
Why You Should Add UnitedHealth (UNH) to Your Portfolio Now
by Zacks Equity Research
The improvement of the economy is likely to support UnitedHealth's (UNH) commercial business recovery.
Teladoc (TDOC) Achieves Momentous 50M Milestone in Visits
by Zacks Equity Research
Of the 50 million visits to Teladoc (TDOC), around one-third took place in the last year alone.
Select Medical (SEM) Shares Fall 9.6% Since Q3 Earnings Miss
by Zacks Equity Research
Select Medical (SEM) reports improved performance in the Rehabilitation Hospital unit for the third quarter.
Why Is Encompass Health (EHC) Up 7.5% Despite Q3 Earnings Miss?
by Zacks Equity Research
Encompass Health (EHC) intends to open 6-10 de novo locations and increase the bed count by 100-150 per annum, till 2026.
Teladoc (TDOC) Up 1.6% Since Q3 Earnings Beat on Higher Visits
by Zacks Equity Research
Teladoc (TDOC) projects total visits in the band of 18.4-18.6 million for 2022.
Why Is Community Health (CYH) Up 27.8% Despite Q3 Earnings Miss?
by Zacks Equity Research
Community Health (CYH) expects labor inflation for 2023 to be within the 3-4% range.
Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Elevance Health (ELV) Beats on Q3 Earnings, Ups '22 EPS View
by Zacks Equity Research
Elevance Health (ELV) is witnessing rapid growth in medical enrollment and expects to keep doing so.
HCA Healthcare (HCA) Eyes 3 Hospital Divestments for $150M
by Zacks Equity Research
The divestment by HCA Healthcare (HCA) is likely to leave LCMC Health and Ochsner Health as the two major hospital care providers in the New Orleans region.
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
by Zacks Equity Research
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
How Much Upside is Left in Inventiva S.A. Sponsored ADR (IVA)? Wall Street Analysts Think 166%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 166.4% in Inventiva S.A. Sponsored ADR (IVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Inventiva S.A. Sponsored ADR (IVA) Could Surge 153%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 152.7% upside potential for Inventiva S.A. Sponsored ADR (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.